Last 34 quarters of trend data · Healthcare · Biotechnology
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
Eton Pharmaceuticals, Inc.'s quarterly P/E stands at 123.4x. EV/EBITDA has compressed 52.0% YoY to 79.9x, reflecting multiple compression or accelerating EBITDA.
| Metric | TTM | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | -192.47 | 123.40 | 77.43 | — | — | — | — | 63.56 | — | — | — | — | 4.85 |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | 11.21 | 8.02 | 5.35 | 6.51 | 5.06 | 5.05 | 7.47 | 3.86 | 2.34 | 3.03 | 3.85 | 3.82 | 1.89 |
| — | +58.9% | -28.5% | +68.6% | +116.6% | +66.5% | +93.9% | +1.1% | +23.7% | -34.5% | +80.8% | -7.8% | -15.5% | |
| P/B Ratio | 33.66 | 25.43 | 17.40 | 25.27 | 15.99 | 14.27 | 14.25 | 9.97 | 6.30 | 6.24 | 7.28 | 6.35 | 5.42 |
| — | +78.2% | +22.1% | +153.5% | +153.9% | +128.9% | +95.6% | +57.0% | +16.2% | -28.7% | +31.5% | +33.3% | +9.1% | |
| P/FCF | 87.95 | 26.55 | — | 12.44 | 12.04 | 41.74 | — | 13.49 | 16.89 | — | — | 30.71 | 3.19 |
| — | -36.4% | — | -7.8% | -28.7% | — | — | -56.1% | +429.3% | — | — | — | -67.0% | |
| EV / EBITDA | 218.99 | 79.86 | 31.48 | — | — | 166.50 | 92.25 | 45.54 | — | — | — | — | 4.64 |
| — | -52.0% | -65.9% | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | 9999.00 | 79.86 | 44.35 | — | — | — | 144.32 | 70.42 | — | — | — | — | 4.02 |
| — | — | -69.3% | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
Eton Pharmaceuticals, Inc.'s operating margin was 9.9% in Q1 2026, down 1.6 pp QoQ and up 12.7 pp YoY. The trailing four-quarter average of 1.9% lags the current quarter, suggesting the recent improvement is above-trend. Gross margin expanded 6.4% YoY, indicating pricing power or improving input costs.
| Metric | TTM | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 53.5% | 60.7% | 61.6% | 35.0% | 63.0% | 57.1% | 55.6% | 61.0% | 62.0% | 62.9% | 49.6% | 62.6% | 80.7% |
| — | +6.4% | +10.7% | -42.7% | +1.6% | -9.2% | +12.0% | -2.6% | -23.2% | -0.4% | -33.7% | -0.1% | +28.7% | |
| Operating Margin | 0.1% | 9.9% | 11.6% | -6.1% | -7.8% | -2.7% | 5.4% | 4.9% | -32.3% | -10.0% | -27.3% | -7.8% | 32.4% |
| — | +465.8% | +114.4% | -223.1% | +75.9% | +72.9% | +119.8% | +163.2% | -199.9% | +79.0% | -318.1% | +91.3% | +277.7% | |
| Net Margin | -5.8% | 6.4% | 7.0% | -8.6% | -13.7% | -9.1% | -5.1% | 6.1% | -33.5% | -10.2% | -30.8% | -8.2% | 38.0% |
| — | +170.4% | +235.7% | -241.3% | +59.2% | +10.7% | +83.4% | +173.7% | -188.2% | +79.7% | -387.5% | +91.3% | +279.5% |
| Metric | TTM | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -18.2% | 5.5% | 6.0% | -8.2% | -10.7% | -6.4% | -3.0% | 4.3% | -21.0% | -5.2% | -13.9% | -3.4% | 32.6% |
| — | +185.1% | +303.4% | -292.2% | +49.2% | -22.8% | +78.8% | +223.6% | -164.4% | +76.1% | -285.4% | +86.2% | +378.6% | |
| ROA | -5.5% | 1.6% | 1.5% | -1.9% | -2.8% | -2.0% | -1.1% | 1.9% | -9.7% | -2.6% | -7.1% | -1.9% | 16.6% |
| — | +183.4% | +241.2% | -200.9% | +71.3% | +24.3% | +85.0% | +200.0% | -158.4% | +76.1% | -282.0% | +86.4% | +346.6% | |
| ROIC | 0.2% | 11.1% | 19.5% | -11.0% | -3.3% | -0.9% | 2.4% | 110.5% | -95.9% | -34.4% | -2033.7% | -42.8% | 132.9% |
| — | +1303.3% | +716.8% | -110.0% | +96.5% | +97.3% | +100.1% | +358.2% | -172.2% | +42.4% | -9656.9% | +33.6% | +565.2% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
Eton Pharmaceuticals, Inc.'s Debt/EBITDA ratio is 5.1x, up from 2.7x last quarter — elevated, raising questions about debt serviceability. The current ratio has weakened 38.8% YoY to 1.21x, tightening the short-term liquidity position. Debt/Equity has risen for 3 consecutive quarters, indicating increasing financial leverage that investors should watch closely.
| Metric | TTM | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 1.19 | 0.40 | 0.35 | 0.14 | 1.28 | 1.23 | 1.22 | 0.27 | 0.36 | 0.33 | 0.35 | 0.34 | 0.37 |
| — | -67.5% | -71.1% | -48.0% | +253.3% | +273.2% | +247.5% | -20.9% | -1.6% | -43.3% | -29.3% | -40.1% | -23.3% | |
| Debt / EBITDA | 7.54 | 5.07 | 2.66 | — | — | 55.39 | 30.40 | 5.50 | — | — | — | — | 1.52 |
| — | -90.8% | -91.3% | — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 1.57 | 1.21 | 1.57 | 1.63 | 1.77 | 1.97 | 2.06 | 1.51 | 1.40 | 1.59 | 1.65 | 2.61 | 2.75 |
| — | -38.8% | -23.5% | +8.1% | +27.0% | +24.3% | +24.4% | -42.3% | -49.2% | -37.8% | -46.6% | -25.8% | -47.1% | |
| Quick Ratio | 1.17 | 0.88 | 1.17 | 1.25 | 1.16 | 1.43 | 1.29 | 1.41 | 1.28 | 1.43 | 1.60 | 2.51 | 2.66 |
| — | -38.8% | -9.2% | -11.4% | -9.8% | -0.1% | -19.0% | -43.9% | -51.8% | -42.5% | -47.0% | -26.5% | -47.3% | |
| Interest Coverage | 0.02 | 2.87 | 2.05 | -0.61 | -1.23 | -0.40 | — | 63.63 | -56.44 | -72.73 | -7.74 | -17.68 | 37.77 |
| — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 34 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying ETON stock.
Eton Pharmaceuticals, Inc.'s current P/E is -192.5x. The average P/E over the last 2 quarters is 100.4x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Eton Pharmaceuticals, Inc.'s current operating margin is 0.1%. Margins have been expanding over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Eton Pharmaceuticals, Inc.'s business trajectory between earnings reports.